Risk of fatal adverse events associated with 17DD yellow fever vaccine

被引:34
|
作者
Struchiner, CJ
Luz, PM
Dourado, I
Sato, HK
Aguiar, SG
Ribeiro, JGL
Soares, RCR
Codeço, TC
机构
[1] Fundacao Oswaldo Cruz, Programa Computac Cientif, BR-21045900 Rio De Janeiro, Brazil
[2] Univ Fed Bahia, Ist Saude Coletiva, Salvador, BA, Brazil
[3] Secretaria Saude Estado Sao Paulo, Sao Paulo, Brazil
[4] Secretaria Saude Estado Minas Gerais, Belo Horizonte, MG, Brazil
[5] Fundacao Nacl Saude, Programa Nacl Imunizacoes, Brasilia, DF, Brazil
来源
EPIDEMIOLOGY AND INFECTION | 2004年 / 132卷 / 05期
关键词
D O I
10.1017/S0950268804002602
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Yellow fever (YF), an acute infectious disease, is endemic in the north and central-west of Brazil. This disease can be prevented by the use of a vaccine. In Brazil, four fatal adverse events have been associated with the YF vaccine used in the country (17DD vaccine). We briefly describe the last two fatalities, and estimate the risk of 17DD-associated fatal adverse events under different epidemiological scenarios. Controversies regarding the appropriate denominator that enters the estimation of risk serve as a motivation for each proposed scenario. The statistical procedures used show optimum behaviour when assessing the risk of rare events. Risk estimates vary from 0(.)043 (95% CI 0(.)017-0(.)110) to 2(.)131 (95% CI 0(.)109-12(.)071) fatalities per million doses administered. The robust estimates of the risk of fatal adverse events we present constitute an important element in future risk-benefit analysis and point to the need for good quality vaccine coverage and adverse-events surveillance data to assess the risk of vaccination. Although vaccination of YF endemic regions is necessary to maintain low disease prevalence, preventive administration of YF vaccine to the entire population should be cautiously analysed.
引用
收藏
页码:939 / 946
页数:8
相关论文
共 50 条
  • [31] Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis
    Ferreira, Clarissa de Castro
    Campi-Azevedo, Ana Carolina
    Peruhype-Magalhaes, Vanessa
    Coelho-dos-Reis, Jordana Grazziela
    do Valle Antonelli, Lis Ribeiro
    Torres, Karen
    Freire, Larissa Chaves
    da Costa-Rocha, Ismael Artur
    Vanderley Oliveira, Ana Cristina
    de Sousa Maia, Maria de Lourdes
    Barbosa de Lima, Sheila Maria
    Domingues, Carla Magda
    Teixeira-Carvalho, Andrea
    Martins-Filho, Olindo Assis
    Henrique da Mota, Licia Maria
    [J]. ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [32] International laboratory network for yellow fever vaccine-associated adverse events
    Barrett, Alan D. T.
    Niedrig, Matthias
    Teuwen, Dirk E.
    [J]. VACCINE, 2008, 26 (43) : 5441 - 5442
  • [33] Yellow fever vaccine and risk of developing serious adverse events: a systematic review
    Porudominsky, Ruben
    Gotuzzo, Eduardo H.
    [J]. REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH, 2018, 42
  • [34] The 17D-204 and 17DD yellow fever vaccines: an overview of major similarities and subtle differences
    Ferreira, Clarissa de Castro
    Campi-Azevedo, Ana Carolina
    Peruhype-Magalhaes, Vanessa
    Costa-Pereira, Christiane
    de Albuquerque, Cleandro Pires
    Muniz, Luciana Feitosa
    de Souza, Talita Yokoy
    Vanderley Oliveira, Ana Cristina
    Martins-Filho, Olindo Assis
    Henrique da Mota, Licia Maria
    [J]. EXPERT REVIEW OF VACCINES, 2018, 17 (01) : 79 - 90
  • [35] Limited replication of yellow fever 17DD and 17D-Dengue recombinant viruses in rhesus monkeys
    Trindade, Gisela F.
    Marchevsky, Renato S.
    De Fillipis, Ana M. B.
    Nogueira, Rita M. R.
    Bonaldo, Myrna C.
    Acero, Pedro C.
    Caride, Elena
    Freire, Marcos S.
    Galler, Ricardo
    [J]. ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS, 2008, 80 (02): : 311 - 321
  • [36] Kinetic Study of Yellow Fever 17DD Viral Infection in Gallus gallus domesticus Embryos
    de Abreu Manso, Pedro Paulo
    Dias de Oliveira, Barbara Cristina E. P.
    de Sequeira, Patricia Carvalho
    Maia de Souza, Yuli Rodrigues
    dos Santos Ferro, Jessica Maria
    da Silva, Igor Jose
    Goncalves Caputo, Luzia Fatima
    Guedes, Priscila Tavares
    Cunha dos Santos, Alexandre Araujo
    Freire, Marcos da Silva
    Bonaldo, Myrna Cristina
    Machado, Marcelo Pelajo
    [J]. PLOS ONE, 2016, 11 (05):
  • [37] The Safety of Yellow Fever Vaccine 17D or 17DD in Children, Pregnant Women, HIV+ Individuals, and Older Persons: Systematic Review
    Thomas, Roger E.
    Lorenzetti, Diane L.
    Spragins, Wendy
    Jackson, Dave
    Williamson, Tyler
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2012, 86 (02): : 359 - 372
  • [38] YELLOW-FEVER 17DD VACCINE VIRUS IS TEMPERATURE SENSITIVE WHEN GROWN IN MOSQUITO C6-36 CELLS
    LEDGER, TN
    SIL, BK
    DUNSTER, LM
    STEPHENSON, JR
    MINOR, PD
    BARRETT, ADT
    [J]. VACCINE, 1992, 10 (10) : 652 - 654
  • [39] Yellow fever vaccine-associated adverse events following extensive immunization in Argentina
    Biscayart, Cristian
    Perez Carrega, Maria Eugenia
    Sagradini, Sandra
    Gentile, Angela
    Stecher, Daniel
    Orduna, Tomas
    Bentancourt, Silvia
    Garcia Jimenez, Salvador
    Pedro Flynn, Luis
    Piran Arce, Gabriel
    Andrea Uboldi, Maria
    Bugna, Laura
    Alejandra Morales, Maria
    Digilio, Clara
    Fabbri, Cintia
    Enria, Delia
    Diosque, Maximo
    Vizzotti, Carla
    [J]. VACCINE, 2014, 32 (11) : 1266 - 1272
  • [40] COMPARISON OF THE NUCLEOTIDE AND DEDUCED AMINO-ACID-SEQUENCES OF THE STRUCTURAL PROTEIN GENES OF THE YELLOW-FEVER 17DD VACCINE STRAIN FROM SENEGAL WITH THOSE OF OTHER YELLOW-FEVER VACCINE VIRUSES
    JENNINGS, AD
    WHITBY, JE
    MINOR, PD
    BARRETT, ADT
    [J]. VACCINE, 1993, 11 (06) : 679 - 681